A critical role for enhanced TGF-α and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  Cozzolino, Mario ^a,b   Lu, Yan ^a   Sato, Tetsuhiko ^a   Yang, Jing ^a   Suarez, Ignacio Gonzalez ^a   Brancaccio, Diego ^b   Slatopolsky, Eduardo ^a   Dusso, Adriana S ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN PAOLO HOSPITAL   (Italy)

^c Department of Internal Medicine   (United States)

Author keywords

Epidermal growth factor receptor; Growth arrest; Renal failure; Secondary hyperparathyroidism; Tyrosine kinase inhibitor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CALCIUM; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CREATININE BLOOD LEVEL; DIETARY INTAKE; ENZYME INHIBITION; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; NONHUMAN; ORGAN SIZE; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 26844544783     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00167.2005     Document Type: Article

References (29)

1. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, and Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510, 2001.
2. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: 32S-40S, 2001.
3. Awwad R, Humphrey LE, Periyasamy B, Scovell W Jr, Li W, Coleman K, Lynch M, Carboni J, Brattain MG, and Howell GM. The EGF/TGF-α response element within the TGF-α promoter consists of a multi-complex regulatory element. Oncogene 18: 5923-5935, 1999.
4. Brown AJ, Zhong M, Ritter C, Brown EM, and Slatopolsky E. Loss of calcium responsiveness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. Biochem Biophys Res Commun 212: 861-867, 1995.
5. 1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275: 6987-6995, 2000.
6. Busse D, Yakes FM, Lenferink AE, and Arteaga CL. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin Oncol 28: 47-55, 2001.
7. Clark AJ, Ishii S, Richert N, Merlino GT, and Pastan I. Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci USA 82: 8374-8378, 1985.
8. Cozzolino M, Dusso AS, and Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12: 2511-2516, 2001.
9. Cozzolino M, Lu Y, Finch J, Slatopolsky E, and Dusso AS. p21WAF1 and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60: 2109-2117, 2001.
10. Denda M, Finch J, and Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28: 596-602, 1996.
11. Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, Morrissey J, and Slatopolsky E. p21(WAF1) and transforming growth factor-α mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 59: 855-865, 2001.
12. Gogusev J, Duchambon P, Stoermann-Chopard C, Giovannini M, Sarfati E, and Drucke TB. De novo expression of transforming growth factor-α in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 11: 2155-2162, 1996.
13. Gonzalez EA and Martin KJ. Renal osteodystrophy: pathogenesis and management. Nephrol Dial Transplant 10, Suppl 3: 13-21, 1995.
14. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, and Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000.
15. Grandis JR, Chakraborty A, Zeng Q, Melhem MF, and Tweardy DJ. Downmodulation of TGF-α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69: 55-62, 1998.
16. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, and Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808, 2001.
17. Naveh-Many T, Rahamimov R, Livni N, and Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96: 1786-1793, 1995.
18. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52: 3-9, 1997.
19. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, and Morin MJ. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748, 1999.
20. Ranson M, Mansoor W, and Jayson G. ZD1839 (IRESSA): a selective EGFR-TK inhibitor. Expert Rev Anticancer Ther 2: 161-168, 2002.
21. Roussanne MC, Lieberherr M, Souberbielle JC, Sarfati E, Drueke T, and Bourdeau A. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. Eur J Clin Invest 31: 610-616, 2001.
22. Sadler GP, Morgan JM, Jasani B, Douglas-Jones A, and Wheeler MH. Epidermal growth factor receptor status in hyperparathyroidism: immunocytochemical and in situ hybridization study. World J Surg 20: 736-742, 1996.
23. Silver J, Sela SB, and Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 6: 321-326, 1997.
24. Slatopolsky E, Brown A, and Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73: S14-S19, 1999.
25. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, and Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97: 2534-2540, 1996.
26. Studer H and Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia-a changing concept: a review focused on the thyroid gland. Endocr Rev 16: 411-426, 1995.
27. Vasef MA, Brynes RK, Sturm M, Bromley C, and Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12: 412-416, 1999.
28. Wells A. EGF receptor. Int J Biochem Cell Biol 31: 637-643, 1999.
29. Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, and Zeng YX. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169: 27-32, 2001.